Lu Daopei Medical Snaps up ￥100M in Series B+

According to VCBeat, Lu Daopei Medical announced that it had raised more than 100 million yuan via a Series B+ financing round, led by In Capital, with China Merchants Securities, Softbank China Venture Capital, Partner Capital Group and existing investor PagodaTree Partners participating. The group previously closed a ￥500 million (US$ 73.2 million) Series B financing round in July this year, led by Singapore's sovereign wealth fund Temasek.

Lu Daopei Medical was founded in 2001 by Lu Daopei, an expert in hematology. After nearly 20 years of development, now the group has a blood disease hospital in Henan, two hospitals in Beijing and a blood disease hospital in Shanghai, becoming China's leading private medical group in the hematology field. 

At present, Lu Daopei Medical has become one of the world's most active hematopoietic stem cell transplant centers. In 2019, 1081 hematopoietic stem cell transplants were successfully completed, making it the largest transplant center in China recently. 70% of them were semi-compatible transplants, which greatly improved the chances of blood tumor patients finding a donor, enabling the majority of patients to be treated.

As a leader in the field of blood diseases, Lu Daopei Medical is actively trying new treatments. Lu Daopei Medical was one of the earliest centers to conduct clinical trials of CAR-T for leukemia in 2015. By cooperating with outstanding CAR-T cell manufacturers in China, the group has accumulated a lot of experience in the field of CAR-T cell therapy and developed the characteristic transplant with CAR-T cells as the bridge. 

In Capital is an asset management firm that emphasis on the healthcare industry. It aims to promote the development of the domestic healthcare industry, provides comprehensive asset management service, and helps entrepreneurs to make strategic decisions.

China Merchants Securities provides investors with all-round professional services of securities investment and financing, including securities trading, securities financing and loan, securities issuance and underwriting, merger & acquisition, asset restructuring, financial consultation, asset management, and investment consultation.